Skip to main content
LNTH
NASDAQ Life Sciences

Lantheus Shareholders Approve Significant Equity Plan Expansion and Board Declassification

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
8
Price
$86
Mkt Cap
$5.566B
52W Low
$47.25
52W High
$108.91
Market data snapshot near publication time

summarizeSummary

Lantheus Holdings, Inc. shareholders approved an amendment to its equity incentive plan, increasing shares reserved for issuance by 2 million, and also voted to declassify the Board of Directors.


check_boxKey Events

  • Equity Incentive Plan Expanded

    Shareholders approved an increase of 2,000,000 shares reserved for issuance under the Amended and Restated 2026 Equity Incentive Plan. This represents a substantial potential future dilution for existing shareholders.

  • Board Declassification Approved

    The company's shareholders approved an amendment to declassify the Board of Directors over a three-year period, transitioning to annual elections for all directors.

  • Director Compensation Limits Revised

    Non-employee director compensation limits were changed from a share-based cap to a dollar-based cap of $1.25 million for the first year of appointment and $750,000 annually thereafter.

  • Routine Annual Meeting Approvals

    Shareholders also elected four Class II directors, provided advisory approval for executive compensation, and ratified the appointment of Deloitte & Touche LLP as independent auditors.


auto_awesomeAnalysis

The approval of the Amended and Restated 2026 Equity Incentive Plan, which adds 2 million shares for future awards, represents a substantial potential dilution for existing shareholders. This capital is intended for employee retention and motivation, crucial for executing the company's strategic initiatives. Concurrently, the company's move to declassify its Board of Directors over a three-year period is a positive corporate governance development, enhancing accountability to shareholders. Investors should weigh the long-term benefits of talent incentives and improved governance against the immediate dilutive impact.

At the time of this filing, LNTH was trading at $86.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $47.25 to $108.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed LNTH - Latest Insights

LNTH
May 07, 2026, 7:44 AM EDT
Filing Type: 10-Q
Importance Score:
7
LNTH
May 07, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
8
LNTH
May 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
LNTH
May 01, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
LNTH
Mar 20, 2026, 4:13 PM EDT
Filing Type: DEF 14A
Importance Score:
7
LNTH
Mar 17, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
LNTH
Mar 10, 2026, 5:18 PM EDT
Filing Type: PRE 14A
Importance Score:
7
LNTH
Mar 06, 2026, 4:04 PM EST
Source: Reuters
Importance Score:
8
LNTH
Mar 02, 2026, 8:31 AM EST
Source: Reuters
Importance Score:
8
LNTH
Feb 26, 2026, 8:00 AM EST
Filing Type: 10-K
Importance Score:
8